Outlook Therapeutics Inc (OTLK)

Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Apr 02, 2025

Mar 31, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025

Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025

Mar 20, 2025

Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com

Mar 20, 2025

Mar 15, 2025

Outlook Therapeutics expands share authorization - Investing.com Australia

Mar 15, 2025

Mar 14, 2025

Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks

Mar 14, 2025

Mar 14, 2025

Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK

Mar 14, 2025

Mar 10, 2025

Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Mar 10, 2025

Mar 09, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 09, 2025

Mar 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Mar 03, 2025

Mar 03, 2025

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025

Mar 03, 2025

INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025

Mar 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire

Mar 03, 2025

Mar 01, 2025

Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire

Mar 01, 2025

Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq

Feb 28, 2025

Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa

Feb 28, 2025

Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq

Feb 28, 2025

Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application - Investing.com

Feb 28, 2025

Feb 28, 2025

Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan

Feb 28, 2025

Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 27, 2025

Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 – OTLK - ACCESS Newswire

Feb 27, 2025

Feb 25, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World

Feb 25, 2025

Feb 24, 2025

HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat

Feb 24, 2025

Feb 23, 2025

Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat

Feb 23, 2025

Feb 21, 2025

vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga

Feb 21, 2025

Feb 21, 2025

HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World

Feb 21, 2025

Feb 20, 2025

What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World

Feb 20, 2025

Feb 19, 2025

Outlook Therapeutics® Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times

Feb 19, 2025

Feb 19, 2025

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Feb 19, 2025

Feb 19, 2025

Can This First-Ever Approved Ophthalmic Bevacizumab Transform Eye Treatment in 2025? - StockTitan

Feb 19, 2025

Feb 19, 2025

Outlook Therapeutics' (OTLK) Neutral Rating Reaffirmed at Chardan Capital - MarketBeat

Feb 19, 2025

Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC Wainwright - MarketBeat

Feb 19, 2025

Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World

Feb 19, 2025

Feb 19, 2025

Outlook Therapeutics’ (OTLK) Neutral Rating Reaffirmed at Chardan Capital - Armenian Reporter

Feb 19, 2025

Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given “Neutral” Rating at Chardan Capital - Defense World

Feb 19, 2025

Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat

Feb 19, 2025

Feb 18, 2025

Outlook Therapeutics stock target cut to $3 at H.C. Wainwright By Investing.com - Investing.com Nigeria

Feb 18, 2025

Feb 18, 2025

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Feb 18, 2025

Feb 18, 2025

Outlook Therapeutics stock target cut to $3 at H.C. Wainwright - Investing.com

Feb 18, 2025

Feb 18, 2025

Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat

Feb 18, 2025

Feb 16, 2025

ONS-5010 shows promise in wet AMD treatment, matching Lucentis - MSN

Feb 16, 2025

Feb 15, 2025

Outlook Therapeutics Reports Strong Earnings and Strategic Progress - MSN

Feb 15, 2025

Feb 15, 2025

Analyzing Scilex (NASDAQ:SCLX) and Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Feb 15, 2025

Feb 14, 2025

Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView

Feb 14, 2025

Feb 14, 2025

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire

Feb 14, 2025

Feb 14, 2025

Outlook Therapeutics Reports Financial Results For First Quarter Of 2025 -February 14, 2025 at 09:07 am EST - Marketscreener.com

Feb 14, 2025